2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. ANGPTL
  5. ANGPTL Inhibitor

ANGPTL Inhibitor

ANGPTL Isoform Comparison

ANGPTL Inhibitors (16):

Cat. No. Product Name Effect Purity
  • HY-P99194
    Evinacumab
    		Inhibitor 99.24%
    Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia.
  • HY-153497A
    Vupanorsen sodium
    		Inhibitor 98.33%
    Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.
  • HY-P990335
    Anti-ANGPTL4 Antibody
    		Inhibitor
    Anti-ANGPTL4 Antibody is a CHO expressed human antibody targeting ANGPTL4. Anti-ANGPTL4 Antibody has a huIgG1-type heavy chain and a huλ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL4 Antibody can be found in Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-177671
    Zodasiran
    		Inhibitor
    Zodasiran is a siRNA targeted to ANGPTL3 in the liver.
  • HY-185318
    Lexosiran
    		Inhibitor
    Lexosiran is a siRNA that inhibits ANGPTL3 (angiopoietin-related protein 3) synthesis, and can be use for the study of antihyperlipidaemic.
  • HY-177671B
    Zodasiran sodium scrambled negative control
    		Inhibitor
    Zodasiran sodium scrambled negative control is the sequence scrambled negative control of Zodasiran sodium.
  • HY-177666B
    Solbinsiran sodium scrambled negative control
    		Inhibitor
    Solbinsiran sodium scrambled negative control is the sequence scrambled negative control of Solbinsiran sodium.
  • HY-163794
    DC371739
    		Inhibitor
    DC371739 is a potent and orally activity PCSK9 inhibitor. DC371739 decreases the mRNA expression of PCSK9 and ANGPTL3. DC371739 decreases the protein expression of PCSK9 and increases the protein expression of LDLR. DC371739 has the potential for the research of hyperlipidemia.
  • HY-153497
    Vupanorsen
    		Inhibitor
    Vupanorsen is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen lowers triglycerides and atherogenic lipoproteins.
  • HY-177671A
    Zodasiran sodium
    		Inhibitor
    Zodasiran sodium is a siRNA targeted to ANGPTL3 in the liver.
  • HY-177666A
    Solbinsiran sodium
    		Inhibitor
    Solbinsiran sodium is a siRNA targeted to hepatic ANGPTL3.
  • HY-185318A
    Lexosiran sodium
    		Inhibitor
    Lexosiran sodium is a siRNA that inhibits ANGPTL3 angiopoietin-related protein 3 synthesis, and can be use for the study of antihyperlipidaemic.
  • HY-177666
    Solbinsiran
    		Inhibitor
    Solbinsiran is a siRNA targeted to hepatic ANGPTL3.
  • HY-P992105
    Corveldebart
    		Inhibitor
    Corveldebart is a monoclonal antibody of immunoglobulin G1-kappa that targets ANGPTL4. Corveldebart can be used as an immunomodulator.
  • HY-153497C
    Vupanorsen sodium scrambled negative control
    		Inhibitor
    Vupanorsen sodium scrambled negative control is the sequence scrambled negative control of Vupanorsen sodium.
  • HY-P990336
    Anti-ANGPTL8 Antibody
    		Inhibitor
    Anti-ANGPTL8 Antibody is a CHO expressed human antibody targeting ANGPTL8. Anti-ANGPTL8 Antibody has a huIgG1-type heavy chain and a huκ-type light chain with a predicted molecular weight (MW) of 150 kDa. An isotype control for Anti-ANGPTL8 Antibody can be found in Human IgG2 kappa, Isotype Control (HY-P99002).